American Journal of Chemical and Biochemical Engineering
Volume 2, Issue 2, December 2018, Pages: 22-26
Received: Sep. 19, 2018;
Accepted: Sep. 29, 2018;
Published: Oct. 30, 2018
Views 334 Downloads 43
Manoochehr Messripour, Department of Medical Biochemistry, Isfahan University of Medical Sciences, Isfahan, Iran
Soheila Moein, Department of Biochemistry and Histology, Bandar-Abbass College of Medicine, Bandar-Abbass, Iran
Myasthenia gravis (MG) is an antibody-mediated autoimmune neuromuscular disease, leading to skeletal muscle weakness. The autoantibodies are against acetylcholine receptor (AChR) of the muscle membrane localized at the neuromuscular junction. The early diagnosis of MG is a key factorfor the advanced medical practice, but, it still remains challenging. The objective of this pilot study was to examine the pattern of serum protein electrophoresis in the animal experimental model of MG. Acetylcholine receptor (AChR) was purified from rat (mail Wistar) leg muscle by affinity chromatography. Four rabbits were immunized on day 1, week 4 and week 8 with purified rat leg muscle AChR and assayed for serum anti-AChR antibody titer on blood samples taken on week 2, week 5 and week 9. Control rabbits received an emulsion of phosphate bufferded saline in the adjuant. The serum anti-AChR anybodies were tittered using quenching fluoroimmunoassay. Electrophoresis separation of the serum proteins was performed on a cellulose acetate membrane. Results showed that Immunizations of rabbits induced muscle weakness in the animals together with elevation of serum anti-AChR antibody. During the course of immunizations, percentage of beta-globulin fraction increased gradually from 15.8% to 41.2% whereas, albumin decreased from 68.3% to 43.8%. As determined by cellulose acetate electrophoresis. These results represent proof-of principle data for diagnosis of the acetylcholine receptor-MG subtypes and severity.
Serum Protein Electrophoretic Pattern in Experimental Myasthenia Gravis, American Journal of Chemical and Biochemical Engineering.
Vol. 2, No. 2,
2018, pp. 22-26.
Gilhus NE, Verschuuren JJ. (2015). Myasthenia gravis: subgroup classification and therapeuticstrategies. Lancet Neurol.14(10):1023-1036
Matthews I, Sims G, Ledwidge S, Stott D, Beeson D, et al. (2002). Antibodies to acetylcholine receptor in parous women with myasthenia: evidence for immunization by fetal antigen. Lab Invest. 82(10):1407-1417.
Gilhus NE (2012). Myasthenia and the neuromuscular junction. Curr Opin Neurol 25(5): 523-529.
Sieb JP (2014). Myasthenia gravis: an update for the clinician, Clin Exp Immunol175(3): 408-418
Gotterer L, Li Y (2016). Maintenance immunosuppression in myasthenia gravis. J Neurol Sci. 369:: 294-302
Mittal MK, Barohn RJ, Pasnoor M, McVey A, Herbelin L, et al. (2011). Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response. J Clin Neuromuscul Dis13: 46-52.
Ing EB, Ing SY, Ing T, Ramocki JA. (2000). The complication rate of edrophonium testing for suspected myasthenia gravis.. Can J Ophthalmol. 35(3):141-144.
Linsell J, Owen WJ, Mason RC, Anggiansah A.(1987). Edrophonium provocation test in the diagnosis of diffuse oesophageal spasm. Br J Surg. 74(8):688-689.
Alboini PE, Damato V, Iorio R, Luigetti M, Evoli A. (2015}. Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review. Neuromuscul Disord. 25(8):646-650
Chiou-Tan FY, Gilchrist JM. (2015). Repetitive nerve stimulation and single-fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: Review of recent literature, Muscle Nerve. 52(3):455-62.
Machado CN. JOÃO A. Kouyoumdjian J. Marchiori P. (2017). Diagnostic accuracy of concentric needle jitter in myasthenia: Prospe ctive study, Muscle Nerve, 55(2), 190–194.
Ha JC, Richman DP. (2015). Myasthenia gravis and related disorders: Pathology and molecular pathogenesis. Biochim Biophys Acta. 1852(4):651-657.
Meriggioli, M. N., & Sanders, D. B. (2012). Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Review of Clinical Immunology, 8(5), 427–438.
Ban J, Phillips WD. (2015), Mouse models of myasthenia gravis. Curr Pharm Des. 21(18):2468-2486.
Oger J, Frykman H. (2015). An update on laboratory diagnosis in myasthenia gravis. Clin Chim Acta. 444:126-131.
Hucho F. Layer P. Kiefer HR, Bandini G. (1976). Photoaffinity labeling and quaternary structure of the acetylcholine receptor from Torpedo californica, Proc. Natl. Acad. Sci. USA. 73(8), 2624-2628,
Lowry OH, Rosebrough MJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem.193: 265-275
Landon J, Moffat AC: (1976). The radioimmunoassay of drugs. A review. Analyst, 101: 225-243.
Messripour M, Moein S. (1997) Indirect quenching fluororeceptor assay of anti-AChR antibodies. Mol. Chem. Neuropathol. 31: 43-51.
Losen M, Martinez-Martinez P, Molenaar PC, et al.(2015) Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors — Recommendations for methods and experimental designs. Exp. neur. 270:18-28.
Chopra B, Abraham R, Abraham A, (2002). Beta-1 Globulin-a potential marker in differentiating multiple sclerosis and acute disseminated encephalomyelitis: a preliminary study, Neurol India. 50(1):41-144
Oosterhuis H.(1964). Myasthenia Gravis with hypergammaglobulinaemia and antibodies J. Neurol. Neurosurg. Psychiat., 27,345-349..
White A. Dougherty T. F. (1948). Role of lymphocytes in normal and immune globulins production, and the mode of release of globulin from lymphocytes. The journal of the American Medical Association (JAMA). 138(12); 890-891.
Bakhiet M. Yu LY. Özenci V. Khan A. Shi FD. (2006). Modulation of immune responses and suppression of experimental autoimmune myasthenia gravis by surgical denervation of the spleen Clin Exp Immunol. 144(2): 290–298.
Molin CJ, Westerberg E, Punga AR.(2017). Profile of up-regulated inflammatory proteins in sera of Myasthenia Gravis patients, Sci. Rep. 7. 39716
Meriggioli MN. Sanders DB. (2012). Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol. 8(5): 427–438.
Li, S., Nai, Q., Lipina, T. V., Roder, J. C., and Liu, F. (2013). alpha7nAchR/NMDAR coupling affects NMDAR function and object recognition. Mol. Brain 6:58-63.